Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 10, 2020 / 06:00PM GMT
Brian Peter Skorney
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

Okay. Hello, everyone. Thanks for joining us this afternoon at Baird's Virtual Health Care Conference, I'm Brian Skorney, I'm one of senior biotech analysts here. Joining us virtually next is the management team from Sarepta Therapeutics. It's a really exciting company. I've been following it for a number of years. I'll let them introduce themselves and the company to all of you before we get into more of a Q&A session. So maybe to start off, Doug, if you could give us a little bit of a background around Sarepta's history and where you guys are focused on right now?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. Thanks a lot, Brian. Thanks for having us today. Two things, one, I'm supposed to remind you that I will -- you'll likely ask me questions that will require me to make forward-looking statements. You should look at our public filings about the risks and uncertainties attended with that. I am the CEO of Sarepta

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot